RESEARCH ARTICLE

Structural view of the regulatory subunit of aspartate kinase from *Mycobacterium tuberculosis*

Qingzhu Yang¹, Kun Yu², Liming Yan², Yuanyuan Li¹, Cheng Chen², Xuemei Li¹✉

¹ National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

² Structural Biology Laboratory, Tsinghua University, Beijing 100084, China

✉ Correspondence: lixm@sun5.ibp.ac.cn

Received August 7, 2011 Accepted September 1, 2011

ABSTRACT

The aspartate kinase (AK) from *Mycobacterium tuberculosis* (*Mtb*) catalyzes the biosynthesis of aspartate family amino acids, including lysine, threonine, isoleucine and methionine. We determined the crystal structures of the regulatory subunit of aspartate kinase from *Mtb* alone (referred to as MtbAK β) and in complex with threonine (referred to as MtbAK β -Thr) at resolutions of 2.6 Å and 2.0 Å, respectively. MtbAK β is composed of two perpendicular non-equivalent ACT domains [aspartate kinase, chorismate mutase, and TyrA (prephenate dehydrogenase)] per monomer. Each ACT domain contains two α helices and four antiparallel β strands. The structure of MtbAK β shares high similarity with the regulatory subunit of the aspartate kinase from *Corynebacterium glutamicum* (referred to as CgAK β), suggesting similar regulatory mechanisms. Biochemical assays in our study showed that MtbAK is inhibited by threonine. Based on crystal structure analysis, we discuss the regulatory mechanism of MtbAK.

KEYWORDS *Mycobacterium tuberculosis*, aspartate kinase, crystal structure, β subunit

INTRODUCTION

As one of the most deadly global diseases, tuberculosis (TB) causes about 9 million active infection cases and 2 million casualties every year (Tomioka and Namba, 2006). Although several chemotherapy drugs, including pyrazinamide, ethambutol, isoniazid and rifampicin are clinically effective, the increasing incidences of multidrug-resistant

(MDR) *Mycobacterium tuberculosis* (*Mtb*) strains and co-infection of *Mtb* and human immunodeficiency virus (HIV) have made the control of *Mtb* more complicated and challenging and the development of novel therapeutic anti-TB drugs in urgent demands (Corbett et al., 2003; Chan and Iseman, 2008).

The biosynthesis pathway of aspartate family amino acids is essential for the development and survival of most bacteria, including *Mtb*. Functioning in the initial step of this pathway, aspartate kinase (AK) catalyzes the phosphorylation of aspartic acid to 4-phospho-L-aspartate, which is subsequently converted to lysine, threonine, isoleucine and methionine (Chaitanya et al., 2010). One of the intermediate products, diaminopimelic acid, contributes to the cross-linked structure of peptidoglycan, the strength and rigidity of bacterial cell wall (Chaitanya et al., 2010). Experiments using *M. smegmatis* showed that the deletion of the gene coding for AK results in significant cell growth inhibition (Rapaport et al., 1996). A negative regulatory feedback of AK by end products has been reported in *Corynebacterium glutamicum* (CgAK) and *Thermus thermophilus* (TtAK) (Cole et al., 1998; Yoshida et al., 2007a; Yoshida et al., 2009). Although no negative feedback regulation has been reported in MtbAK, a similar inhibitory regulation may exist in MtbAK. Based on these critical roles played by AK in amino acid biosynthesis pathway, which is absent in human, AK has been identified as a potential drug target in *Mtb*, especially in MDR-*Mtb* (Cirillo et al., 1994; Chaitanya et al., 2010).

Two types of AKs exist, homo-oligomeric and hetero-tetrameric. AKI from *Arabidopsis thaliana* is an example of homo-oligomeric AK (Rognes et al., 1980; Mas-Droux et al., 2006; Schuldt et al., 2011). AKs from *M. tuberculosis* (Cirillo et al., 1994; Gilker J.M., 1997; Schuldt et al., 2011), C.

glutamicum (Yoshida et al., 2007a) and *T. thermophiles* (Nishiyama et al., 1995; Yoshida et al., 2007b) belong to the second type. The hetero-tetrameric $\alpha_2\beta_2$ AK contains α and β subunits, which are encoded by in-frame overlapping genes (Schuldt et al., 2011). The catalytic domain of hetero-tetrameric $\alpha_2\beta_2$ AK is composed of the N-terminal region of the α subunit and the regulatory domain comprises the β subunit and the C-terminal region of the α subunit (Gilker J.M., 1997; Yoshida et al., 2007a, 2007b; Schuldt et al., 2011). A key feature of the regulatory domain of AK is the conserved ACT domain [aspartate kinase, chorismate mutase, and TyrA (prephenate dehydrogenase)] (Aravind and Koonin, 1999; Chipman and Shaanan, 2001), which comprises a $\beta\alpha\beta\alpha\beta$ fold and is expected to play a regulatory role when binding to small molecules (Grant, 2006). The monofunctional AKs can be divided into three classes depending on the number of ACT domain in the regulatory domain. Class I has two ACT domains per monomer; class II contains two ACT domains per subunit and class III has four ACT domains per monomer. Homo-oligomeric AK belongs to class I or class III, while the hetero-tetrameric AK belongs to class II (Robin et al., 2010). Aspartokinase from *M. tuberculosis* which has 421 residues is

a monofunctional $\alpha_2\beta_2$ -type aspartokinase encoded by a single gene. The α subunit is comprised of residues 1–421. The β subunit from *M. tuberculosis* is comprised of residues 250–421. The residues 250–421 of C-terminal region of the α subunit and the β subunit make up the regulatory domain. Each subunit contains two ACT domains (Gilker J.M., 1997; Cole et al., 1998; Fleischmann et al., 2002; Schuldt et al., 2011).

Crystal structures of several homo-oligomeric AKs and hetero-tetrameric $\alpha_2\beta_2$ -type AKs have been reported previously, such as the homo-oligomeric AK from *A. thaliana* (PDB code: 2CDQ) (Mas-Droux et al., 2006), the β subunit of $\alpha_2\beta_2$ -type AK from *C. glutamicum* (PDB code: 2DTJ) (Yoshida et al., 2007a), the β subunit of $\alpha_2\beta_2$ -type AK from *T. thermophiles* (TtAK β) (PDB code: 2ZHO and 2DT9) (Yoshida et al., 2009) and the full-length $\alpha_2\beta_2$ -type AK from *C. glutamicum* (PDB code: 3AAW, 3AB2 and 3AB4) (Yoshida et al., 2010). However, no crystal structure of MtbAK has been reported and the regulatory mechanism of MtbAK is poorly understood. In this study, the crystal structures of MtbAK β alone (MtbAK β -free) and in complex with threonine (MtbAK β -Thr) have been determined at resolutions of 2.6 Å and 2.0 Å,

Table 1 Data collection statistics

Parameter	MtbAK β -free	MtbAK β -Thr
Data collection statistics		
Cell parameters (Å, deg)	a = b = 64.8 Å, c = 137.0 Å, $\alpha = \beta = \gamma = 90^\circ$	a = b = 62.4 Å, c = 137.3 Å, $\alpha = \beta = \gamma = 90^\circ$
Space group	I41	I41
Wavelength used (Å)	1.0000	0.9800
Resolution range (Å)	50.00–2.60 (2.64–2.60)	50.00–2.00 (2.03–2.00)
No. of all reflections	42061	87898
No. of unique reflections	8654	17555
Completeness (%)	99.7 (99.0) ^c	99.7 (99.9) ^c
I/ σ (I)	21.3 (3.1) ^c	40.4 (3.4) ^c
R _{merge} ^a (%)	13.6 (65.6) ^c	4.3 (60.4) ^c
Refinement statistics		
No. of reflections used ($\sigma(F) > 0$)	8263	17540
R _{work} ^b (%)	20.6	21.9
R _{free} ^b (%)	26.2	27.7
r.m.s.d. bond distance (Å)	0.021	0.007
r.m.s.d. bond angle (deg)	1.990	1.222
Overall average B factor (Å ²)	48.0	52.4
Ramachandran plot (excluding Pro and Gly)		
Res. in most favored regions	129 (90.2%) ^c	125 (87.4%) ^c
Res. in additionally allowed regions	13 (9.1%) ^c	14 (9.8%) ^c
Res. in generously allowed regions	1 (0.7%) ^c	1 (0.7%) ^c

^a $R_{\text{merge}} = \sum h \sum l |I(h) - \langle I(h) \rangle| / \sum h \sum l I(h)$, where $\langle I(h) \rangle$ is the mean of the observations $I(h)$ of reflection h .

^b $R_{\text{work}} = \sum (|F_p(\text{obs})| - |F_p(\text{calc})|) / \sum |F_p(\text{obs})|$; R_{free} is an R factor for a selected subset (5%) of the reflections that was not included in prior refinement calculations.

^c Numbers in parentheses are the corresponding values for the highest resolution shell.

respectively. Biochemical assay showed that MtbAK is inhibited by threonine. The regulatory mechanism of MtbAK is further analyzed and discussed, based on the conformational differences between MtbAK-free and MtbAK-threonine.

RESULTS AND DISCUSSION

Overall structure of MtbAK β -free and MtbAK β -Thr

The crystal structure of the MtbAK β -free was determined at 2.6 Å by molecular replacement method with a final R_{work} value of 20.6% ($R_{\text{free}} = 26.2\%$) using the regulatory subunit of $\alpha_2\beta_2$ -type AK from *C. glutamicum* (PDB code: 2DTJ) (Yoshida et al., 2007a) as a search model. The space group of the crystal is I41 with unit cell parameters of $a = b = 64.8$ Å, $c = 137.0$ Å, $\alpha = \beta = \gamma = 90^\circ$. There is one MtbAK β molecule (166 residues) per asymmetric unit with a Matthews coefficient of $3.7 \text{ Å}^3/\text{Da}$, corresponding to 67% solvent content (Matthews, 1968). The electron densities of residues 303–304 and 418–421 are not observed on the density map.

The crystal structure of MtbAK β -Thr was determined at 2.0 Å resolution with a final R_{work} value of 21.9% ($R_{\text{free}} = 27.7\%$) by the molecular replacement method using the structure of MtbAK β -free as a search model. The space group of the crystal is I41 with unit cell parameters of $a = b = 62.4$ Å, $c = 137.3$ Å, $\alpha = \beta = \gamma = 90^\circ$. There is one monomer (166 residues) containing one Thr molecule per asymmetric unit with a Matthews coefficient of $3.3 \text{ Å}^3/\text{Da}$, corresponding to 63% solvent content (Matthews, 1968). The electron densities of residues 303–304 and 418–421 are not observed on the map. We summarized final refinement statistics in Table 1.

Each MtbAK β contains two perpendicular ACT domains. The N-terminal ACT will be referred to as ACT1 and C-terminal ACT as ACT2. Each ACT is composed of four-stranded β sheets and two α -helices and are connected by a short loop of two amino acids.

ACT1 and ACT2 are topologically different. ACT1 has a typical $\beta\alpha\beta\beta\alpha\beta$ topology, while ACT2 domain displays a $\beta\beta\alpha\beta\beta\alpha\beta$ topology, with the first β strand in ACT2 in front of ACT1. Similar arrangement of the two ACT domains is also found in AK from *C. glutamicum* (CgAK) (Yoshida et al., 2007a), AKIII from *E. coli* (EcAKIII) (Kotaka et al., 2006) and AK from *M. jannaschii* (MjAK) (Faehnle et al., 2006) and implies a peculiar structural feature of the AK regulatory domain.

The structure of MtbAK β -Thr contains a monomer and one Thr molecule. The Thr molecule is bound at site 1 in MtbAK β while in homo-oligomeric AKs, two inhibitors are bound at one binding pocket (Kotaka et al., 2006; Yoshida et al., 2009).

The main difference between the structures of MtbAK β -free and MtbAK β -Thr is the outward shifts of the β strands around Thr-binding site in MtbAK β -Thr (Fig. 5B). The rmsd for

Figure 1. Reaction catalyzed by MtbAK. The first step in the biosynthesis of the aspartate group of amino acids, phosphorylation of aspartic acid, is catalyzed by MtbAK.

α between the two structures is about 0.9 Å, which will be discussed in detail later.

Comparison with the structures of β subunits from other AKs

MtbAK β monomer shares high similarity with CgAK β and TtAK β , according to superimposition of the structures of MtbAK β -free, CgAK β (PDB code: 2DTJ) and TtAK β (PDB code: 2ZHO) (Yoshida et al., 2009). The β subunits from these three AKs all have two ACT domains with a characteristic $\beta\alpha\beta\beta\alpha\beta$ structure. The high structural similarity between MtbAK β , CgAK β and TtAK β suggests similar regulatory mechanisms for these regulatory subunits. However, there are two major differences among the three β subunits (Fig. 3A and 3B). First, CgAK β contains an extra β strand β_9 which is not part of the C-terminal ACT2. According to recent studies, this strand is proposed to be crucial for the biological roles of CgAK, which may be different from MtbAK and TtAK (Yoshida et al., 2010). Second, the residues 54–55 of the β_3 - β_4 loop region are disordered in the crystal structure of MtbAK β , implying high flexibility in this region. Third, about 5 residues at the N-terminus of CgAK β and TtAK β are missing due to lack of electron density, while those of MtbAK β are observed clearly from electron density map. Although a few other differences are found, they are likely due to the amino acid sequence differences and are not further analyzed.

Figure 2. The overlapping genes of MtbAK and crystal structure of MtbAKβ. (A) The α subunit and β. subunit of MtbAK are shown by striped and dotted bars respectively. The β subunit of MtbAK was used for structural study in our work. (B) Overall structure of MtbAKβ-free monomer. The ACT1 and ACT2 domains are indicated by light pink and sand respectively. (C) Overall structure of MtbAKβ-Thr monomer. ACT1 and ACT2 domains are indicated by green and yellow respectively. Bound Thr is shown as orange spheres. (D) The structure of homodimeric MtbAKβ-Thr. The molecules are colored in green and cyan respectively. Bound Thr is shown as orange spheres. The interface, consisting of residues essential for intermolecular contact (distance less than 3.6 Å), is colored in red. (E) Elution profiles of MtbAKβ in the presence and absence of 10 mmol/L Thr. Blue and red lines indicate in the absence and presence of 10 mmol/L Thr, respectively. Elution volumes for BSA (67.0 kDa), ovalbumin (43.0 kDa), carbonic anhydrase (29.0 kDa) and ribonuclease A (13.7 kDa) are indicated by a, b, c, and d, respectively. Data were resolved and plotted by MATLAB (<http://www.mathworks.com/products/matlab>).

Figure 3. Comparison of the structure of MtbAKβ-Thr monomer with CgAKβ-Thr and TtAKβ-Thr monomers. (A) Superimposition of MtbAKβ-Thr monomer (green) onto CgAKβ-Thr (PDB code: 2DTJ) monomer (magenta). CgAKβ-Thr contains an extra β strand at the C terminus. Bound threonines in MtbAKβ-Thr and CgAKβ-Thr are shown as orange and magenta sticks respectively. (B) Superimposition of MtbAKβ-Thr monomer (green) onto TtAKβ-Thr (PDB code: 2DT9) monomer (lightblue). Bound threonines in MtbAKβ-Thr and TtAKβ-Thr are shown as orange and magenta sticks respectively. Positions of difference are marked by dashed boxes. (C) Structure-based sequence comparison of the β subunit of aspartate kinases from *M. tuberculosis*, *C. glutamicum* and *T. thermophilus*. Secondary structure elements of the β subunit of aspartokinase from *M. tuberculosis* are shown at top of the alignment.

Analysis of the oligomeric state of MtbAKβ

TtAKβ is in equilibrium of monomer and dimer conformations. Thr and / or concentrations of TtAKβ facilitate the dimerization of TtAKβ (Yoshida et al., 2009). Similar to TtAKβ, threonine can induce the dimerization of CgAKβ (Yoshida et al., 2007a). To examine the effect of threonine on MtbAKβ, we investigated the oligomeric state of MtbAKβ in the presence and absence of Thr by two methods, namely gel filtration chromatography and analytical ultracentrifugation.

Gel filtration chromatography profile showed that MtbAKβ was exactly eluted at the same volume in the presence and absence of 10 mmol/L threonine, giving an observed molecular weight of 35.0 kDa (Fig. 2E). These results suggest

that addition of Thr does not affect the oligomeric state of MtbAKβ.

Analytical ultracentrifugation confirmed that the estimated molecular mass of MtbAKβ in the presence of 10 mmol/L Thr is 37.0 kDa. Considering the mass of a monomer is 20.4 kDa, these results show that MtbAKβ is in a dimer conformation with or without threonine. However, in the case of CgAK, the equilibrium favors the monomer conformation in the absence of threonine, suggesting that the binding affinity between β subunits is stronger in MtbAK.

CgAK dissociates into α and β subunits during purification in the absence of threonine. The β subunit of TtAK is eluted from the column later than the α subunit in the absence of threonine in gel filtration assays (Yoshida et al., 2009). From the binding assay of the α subunits and β subunits from

Figure 4. Thr-binding site and the enzyme activity study. (A) Thr-binding site in MtbAKβ-Thr. Green, chain X; blue, chain Y; orange, Thr. Residues from chain Y are shown with asterisks. Number after the residue represents the residue number from β subunit. (B) Vacant Thr-binding site in MtbAKβ-free. sand, chain X; skyblue, chain Y; Residues from chain Y are shown with asterisks. Number after the residue represents the residue number from β subunit. (C) Inhibition profile of MtbAK by threonine. The histograms represent the mixture with 10 mmol/L Thr, 10 mmol/L Lys, 10 mmol/L Thr plus 10 mmol/L Lys and without inhibitor as control, respectively.

MtbAK, the β subunits containing His₆ tags at the C terminus were bound to the α subunits in the absence of threonine, that is to say, MtbAK is purified in the $\alpha_2\beta_2$ form in the absence of threonine. Moreover, the α subunit and β subunit are eluted together from the column in the absence of threonine in gel filtration assays. From these observations, we conclude that the α subunit of MtbAK can interact with the β subunit without threonine, and the interaction is stronger than those of TtAK and CgAK.

Dimeric assembly of MtbAK β

Crystal structure showed that two molecules of MtbAKβ-free, which are connected by a crystallographic screw fourfold axis, form a sphere-like homodimer with a 1814 Å² intra-dimer interface, while the MtbAKβ-Thr homodimer has an interface of 2065 Å² (Fig. 2D). Multitudinous hydrophobic interactions, hydrogen bonds, salt bridges and van de Waals interactions

between the two monomers (Table 2) suggest that the homodimer is stable. MtbAK is a heterotetramer with an $\alpha_2\beta_2$ configuration (Schuldt et al., 2011). As the β subunit of MtbAK is identical to the C-terminal portion of the α subunit, the dimeric structure could characterize the crystal structure of the regulatory region of an $\alpha_2\beta_2$ -heterodimer. This is in accordance with the results of similar $\alpha_2\beta_2$ AKs such as TtAK and CgAK (Yoshida et al., 2009; Yoshida et al., 2010). It is not clear whether the homodimers described above have functional relevance and more biochemical data are needed to test this hypothesis.

Thr-binding site

The crystal structure of MtbAKβ-Thr showed that the electron density of a threonine molecule is located at site 1 in the interface between ACT1 domain and ACT2 domain from a different chain and is solvent inaccessible. The structure of

Figure 5. Comparison of a single inhibitor-binding unit between unliganded MtbAK β and MtbAK β -Thr. (A) Superposition of the inhibitor-binding units of unliganded MtbAK β and MtbAK β -Thr. MtbAK β -Thr and unliganded MtbAK β are in green and sand, respectively. The Thr molecule is depicted as a stick model. ACT1 shows the C α models of the Y chain (residues 1–11 and 95–168) in MtbAK β -Thr and unliganded MtbAK β , and ACT2 shows C α models of the X chain (residues 12–94) in MtbAK β -Thr and unliganded MtbAK β . (B) Domain motion in MtbAK β caused by Thr binding. The structures of MtbAK β -Thr and unliganded MtbAK β are shown in green and sand, respectively. Domain motion was resolved using DYNDOM (Hayward and Lee, 2002). A dash line demonstrates hinge axis of the movement.

Table 2 Analysis of the dimer interface by the Protein–Protein Interaction Server (<http://www.biochem.ucl.ac.uk/bsm/PP/server>)

Interface parameters	MtbAK β -free	MtbAK β -Thr
Interface accessible surface area ($\text{\AA}^2$)	1814	2065
% of monomer accessible surface area	20.99	23.86
% Polar residues in interface	24.49	24.07
% Non-polar residues in interface	51.02	50.00
% Charged residues in interface	24.49	25.93
Hydrogen bonds	6	22
Salt bridges	26	62

MtbAK β -Thr is similar to that of CgAK β monomer bound by a threonine. The rmsd for C α between these two structures is 0.9 $\text{\AA}$. Threonine is stabilized by ionic bonds between the Asp²⁷⁴⁽²⁵⁾-O ^{Ω 2} and the amino group of threonine, and the Gln²⁹⁸⁽⁴⁹⁾-N ^{ϵ 2} and the hydroxyl group of threonine. The amino group of threonine is stabilized by Ile126 O and Asn125- O ^{Ω 1} via hydrogen bonds, while the carboxyl group of threonine forms a hydrogen bond with Ile126 N. The methyl group of

threonine is recognized by hydrophobic interactions with Thr59 and Ile61. Two water molecules around two oxygen atoms of the carboxyl group of threonine are involved in a hydrogen-bond network between the carboxyl group of threonine, Ala30 N, Ala31 N, Gly28 N, and Val124 O. Therefore, the carboxyl group of Thr is stabilized by positively charged main chain atoms. As observed in CgAK β and TtAK β , the carboxyl group of Thr is located near the Pro²⁷(β)-Gly²⁸(β) sequence at the N terminus of the β subunit, implying that the positive charges of the helix dipole participate in the recognition of the carboxyl group. Thus, Thr is recognized by several ionic bonds, hydrogen bonds, and hydrophobic interactions. Most residues interacting with threonine in MtbAK β are conserved in CgAK β and TtAK β and these residues may constitute a conserved inhibitory binding pocket in $\alpha_2\beta_2$ -type AKs, which might share similar regulatory mechanisms.

Enzymatic assays in our study have shown that MtbAK is significantly inhibited by the addition of threonine but not lysine (Fig. 4C). Thus, threonine may be important for the regulation of MtbAK enzymatic activity.

Conformational change of MtbAK β upon Thr binding and its implications in the regulatory mechanism

One difference between MtbAK β -Thr and MtbAK β -free is that

the β strands around the Thr-binding site exhibit outward shifts in the presence of Thr, with 10.5° rotation of the ACT2 domain from the ACT1 domain (Fig. 5B). MtbAK and CgAK are both heterotetramer with an $\alpha_2\beta_2$ configuration. The structure of MtbAK β monomer shares high similarity with CgAK β monomer. The regulatory region of CgAK is composed of a dimer, and enzymatic activity of CgAK is inhibited by both Lys and Thr in a concerted manner. One threonine molecule is bound at site 1 in CgAK β , like MtbAK β -Thr (Yoshida et al., 2007a). Thus, a similar conformational change is anticipated for the two enzymes upon the absence or presence of Thr and the regulatory mechanism of MtbAK is discussed.

In CgAK, mutations of residues in the β 3- β 4 loop which are close to site 1 made the enzyme insensitive to lysine (Yoshida et al., 2007a). Lys is bound to site 2 between ACT1 and ACT2, which is from a different chain (Yoshida et al., 2010). The influence of residues in the β 3- β 4 loop on the catalytic regulation of CgAK leads to the analysis of the β 3- β 4 loop of MtbAK. In MtbAK, outward shifts of β 3- β 4 triggered by Thr binding induce shifts surrounding site 2. It is likely that a conformational change at site 2 triggered by Thr binding at site 1 will induce an additional Thr binding at site 2 in MtbAK. Additionally, in MtbAK, the Pro27- Gly28 sequence at the N terminus of the β subunit participates in the binding of Thr. The dihedral angle of Gly28 has a significant change upon Thr binding. In chain A of MtbAK-free, $\Phi = 107.47^\circ$, $\Psi = -39.64^\circ$, while in MtbAK-Thr, $\Phi = 94.26^\circ$, $\Psi = -10.1^\circ$ in chain A. The Pro27- Gly28 sequence is conserved in CgAK for the recognition of Thr. The equivalent Pro-Gly motif Pro109- Gly110 surrounding site 2 in CgAK β is conserved in MtbAK β , and the dihedral angle of Gly110 also changes upon Lys binding at site 2. In chain O of Thr-bound CgAK, $\Phi = 85.81^\circ$, $\Psi = -5.77^\circ$, while $\Phi = 89.92^\circ$, $\Psi = -0.75^\circ$ in chain O of CgAK, upon Thr and Lys binding. According to the allowed or generously allowed regions on the Ramachandran plot, it is likely that a dramatic change can occur in the dihedral angle of Gly110 in MtbAK β . Thus, we propose that the Pro-Gly sequence is important for the induction of conformational change upon inhibitor binding in $\alpha_2\beta_2$ -type AKs. However, more studies are needed to confirm whether an additional Thr is bound at site 2 and inhibits MtbAK.

There are structural differences between MtbAK β and CgAK β . An additional β strand β 9 was found at the C terminus in CgAK β . This β strand is proposed to participate in the inhibition induced by Thr and Lys in CgAK. After Thr and Lys binding, β 1(β) shifts from β 9(β) to β 5(α), facilitating the adoption of an inactive closed conformation (Yoshida et al., 2010). However, MtbAK β does not have this additional β strand. In addition, the disordered residues in the β 3- β 4 loop region in MtbAK β indicate that this is a flexible region. These may cause the differences in the regulatory mechanisms between MtbAK and CgAK.

CONCLUSIONS

Aspartate kinase from *Mtb* catalyzes the biosynthesis of the aspartate family amino acids, including lysine, threonine, isoleucine, and methionine. Since AK is critical for the survival of *Mtb* and does not exist in humans, it is an important target for anti-TB drugs.

We reported the crystal structures of the MtbAK-free and MtbAK-Thr at high resolutions. The structure of MtbAK β , composed of four-stranded β -sheets and two α -helices on both sides respectively, contains conserved ACT domains and shares high similarity to CgAK β and TtAK β . Enzymatic assays showed that Thr binding inhibits MtbAK activity. Most residues involved in Thr binding are conserved in CgAK β and TtAK β . We propose that these residues form an inhibitory binding pocket in $\alpha_2\beta_2$ -type AKs and similar regulatory mechanisms might be shared by AKs from different species. According to the structure comparison of MtbAK-free and MtbAK-Thr, we analyzed the regulatory mechanism of MtbAK and speculated that Thr binding at site 1 may facilitate the binding of an additional Thr molecule at site 2 and inhibit the enzyme. The further elucidation of the regulatory mechanism of MtbAK relies on the crystal structure of $\alpha_2\beta_2$ -form MtbAK in complex with Thr. The crystal structures of MtbAK β and MtbAK-Thr we reported here provide useful information for drug design targeting MtbAK. Threonine analogs and other small molecules, which have high affinity for MtbAK, may induce similar conformational changes and enzymatic activity inhibition. These potential drugs may constitute an efficacious treatment for MDR and TB/HIV co-infection cases.

MATERIALS AND METHODS

Cloning

The β subunit of aspartate kinase gene was amplified by PCR and inserted into the expression vector pET-28a (Novagen) using *Nde*I and *Xho*I sites. The resultant MtbAK β protein contains a His₆ tag at the C terminus. The genes encoding the α and β subunits of MtbAK are cloned into the pET-26b expression vector (Novagen) between *Nde*I/*Eco*RI sites, and *Eco*RI/*Xho*I sites led by a typical ribosome binding site respectively. The resulting β subunit contains a His₆ tag at the C terminus.

Expression and purification

The recombinant pET-28a plasmid was transformed into *E. coli* strain Transetta (DE3) Chemically Competent Cells (TransGen Biotech). The cells were grown in LB broth containing 50 mg/L kanamycin at 303K. When the OD₆₀₀ of the culture reached 0.6, 0.1 mmol/L isopropyl β -D-thiogalactopyranoside (IPTG) was added to induce gene expression for 12 h. The cells were then harvested by centrifugation. The pellets were lysed in buffer A (20 mmol/L Tris-HCl pH 7.5 and 150 mmol/L NaCl) and subsequently disrupted by high pressure cell cracker. Cell debris was removed by centrifugation

at 14,000 rpm for 45 min at 277 K. MtbAK β was purified by Ni-NTA affinity chromatography and the protein was eluted by buffer A supplemented with 300 mmol/L imidazole and subsequently subjected to gel-filtration chromatography. The purity of target protein was confirmed to be more than 92% by SDS-PAGE and coomassie blue stain. The protein was concentrated to 7.5 mg/mL and stored at 193 K. The expression and purification of MtbAK in the $\alpha_2\beta_2$ form was identical to MtbAK β .

Crystallization

Crystallization of the β subunit of *M. tuberculosis* aspartokinase was conducted at 290 K using the hanging-drop vapor-diffusion technique. The purified protein was in buffer A for crystallization. Crystals were formed by mixing 1 μ L of the MtbAK β solution with 1 μ L of reservoir solution. Small crystals appeared after 2 days of growth in 0.1 mol/L Tris pH 8.5 and 2.0 mol/L ammonium phosphate. Well-shaped crystals having a final size of 30 μ m $\times$ 30 μ m $\times$ 60 μ m were obtained after optimization. Good crystals which diffract to 2.6 Å were found in crystallization buffer containing 0.1 mol/L Tris pH 8.5 and 1.8 mol/L ammonium phosphate. 10 mmol/L Thr was added to buffer A for the crystallization of MtbAK β -Thr. Well-shaped crystals of MtbAK β -Thr having a final size of 50 μ m $\times$ 50 μ m $\times$ 100 μ m were obtained in the same reservoir solution and diffracted to 2.0 Å. The crystals were transferred into cryoprotectant solution containing synthetic mother solution and 25% (v/v) glycol. Then the crystals were flash-cooled in liquid nitrogen for the collection of X-ray diffraction data.

X-ray data collection, processing and structure determination

The crystal of MtbAK β diffracts to 2.6 Å at 100 K using an MAR 165 CCD detector with 1.0000 Å wavelength on beamline 1W2 at Beijing Synchrotron Radiation Facility (BSRF). The HKL2000 package (Otwinowski and Minor, 1997) was used for data processing, integrating and scaling. The crystals of MtbAK β belong to the I41 space group with unit cell parameters of $a = b = 64.8$ Å, $c = 137.0$ Å, $\alpha = \beta = \gamma = 90^\circ$. The crystal contains one molecule per asymmetric unit with a Matthews coefficient of 3.7 Å³/Da, corresponding to 67% solvent content (Bailey, 1994). The PHASER program (McCoy et al., 2007) was used to perform molecular replacement using the crystal structure of β subunit of *C. glutamicum* (PDB code: 2DTJ) (Yoshida et al., 2007a) as a template. COOT (Emsley and Cowtan, 2004) and REFMAC were used for subsequent manual model building and structure refinement.

The crystal of MtbAK β -Thr diffracted to 2.0 Å resolution at 100 K using an ADSC Q315 CCD detector with 0.9800 Å wavelength in BL17A (Photon Factory, Japan). The HKL2000 package (Otwinowski and Minor, 1997) was used for data processing, integrating and scaling. The crystals of MtbAK β -Thr belong to the I41 space group with unit cell parameters of $a = b = 62.4$ Å, $c = 137.3$ Å, $\alpha = \beta = \gamma = 90^\circ$. The crystal contains one molecule per asymmetric unit with a Matthews coefficient of 3.3 Å³/Da, corresponding to 63% solvent content (Bailey, 1994). The PHASER program (McCoy et al., 2007) was used to perform molecular replacement to find the correct solution using the crystal structure of MtbAK β as a template. COOT (Emsley and Cowtan, 2004) and PHINEX (Adams et al., 2002) were used for subsequent manual model building and structure refinement. We summarized the final refinement statistics in Table 1

and the structural figures were drawn using PyMOL (DeLano and Lam, 2005).

Binding assay of the α subunits and β subunits from MtbAK

For the binding assay of the α subunits and β subunits from MtbAK, the two proteins were expressed simultaneously and purified as above. About 2 μ g of the α subunits and 1 μ g of His-tagged MtbAK β were added to the column having 300 μ L of 30% Ni-NTA slurry with the bottom outlet capped at 4°C for 1.5 h. Then the cap was removed and the Ni-NTA resin-coupled proteins were washed with buffer A containing 150 mmol/L imidazole 6 times. The proteins were eluted with buffer A containing 150 mmol/L imidazole. Eluted proteins were analyzed by 15% SDS-PAGE and coomassie blue stain.

Enzymatic assay

The activity of MtbAK was assayed by the method used by Black and Wright (Black and Wright, 1955). The 200 μ L reaction mixture contained 200 mmol/L Tris-HCl, pH 7.5, 10 mmol/L MgCl₂, 500 mmol/L ammonium sulfate, 10 mmol/L potassium aspartate, 10 mmol/L ATP, 10 mmol/L threonine or lysine, 160 mmol/L NH₂OH-HCl (neutralized with KOH), and enzyme at appropriate concentrations. After incubation at 30°C for 30 min, the reaction was stopped by adding 300 μ L 5% (w/v) FeCl₃ solution, and absorbance was monitored at 540 nm.

ACKNOWLEDGEMENTS

We thank staffs from Beijing Synchrotron Radiation Facility for their technical help with the data collection and Lei Wei for his assistance in manuscript revision. This work was supported by the National Basic Research Program (973 Program) (Grant Nos. 2011CB915501 and 2011CB910304) and National Major Project (Grant Nos. 2009ZX10004-304 and 2009ZX10004-802).

ABBREVIATIONS

AK, aspartate kinase; CgAK, aspartate kinase from *Corynebacterium glutamicum*; CgAK β , the regulatory subunit of aspartate kinase from *Corynebacterium glutamicum*; Mtb, *Mycobacterium tuberculosis*; MtbAK, aspartate kinase from *Mycobacterium tuberculosis*; MtbAK β , the regulatory subunit of aspartate kinase from *Mycobacterium tuberculosis*; TtAK, aspartate kinase from *Thermus thermophilus*; TtAK β , the regulatory subunit of aspartate kinase from *Thermus thermophilus*; TyrA, prephenate dehydrogenase

REFERENCES

- Adams, P.D., Grosse-Kunstleve, R.W., Hung, L.W., Ioerger, T.R., McCoy, A.J., Moriarty, N.W., Read, R.J., Sacchettini, J.C., Sauter, N.K., and Terwilliger, T.C. (2002). PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallogr D Biol Crystallogr* 58, 1948–1954.
- Aravind, L., and Koonin, E.V. (1999). Gleaning non-trivial structural, functional and evolutionary information about proteins by iterative database searches. *J Mol Biol* 287, 1023–1040.
- Bailey, S., and the Collaborative Computational Project, Number 4. (1994). The CCP4 suite: programs for protein crystallography. *Acta*

- Crystallogr D Biol Crystallogr 50, 760–763.
- Black, S., and Wright, N.G. (1955). beta-Aspartokinase and beta-aspartyl phosphate. *J Biol Chem* 213, 27–38.
- Chaitanya, M., Babajan, B., Anuradha, C.M., Naveen, M., Rajasekhar, C., Madhusudana, P., and Kumar, C.S. (2010). Exploring the molecular basis for selective binding of *Mycobacterium tuberculosis* Asp kinase toward its natural substrates and feedback inhibitors: a docking and molecular dynamics study. *J Mol Model* 16, 1357–1367.
- Chan, E.D., and Iseman, M.D. (2008). Multidrug-resistant and extensively drug-resistant tuberculosis: a review. *Curr Opin Infect Dis* 21, 587–595.
- Chipman, D.M., and Shaanan, B. (2001). The ACT domain family. *Curr Opin Struct Biol* 11, 694–700.
- Cirillo, J.D., Weisbrod, T.R., Pascopella, L., Bloom, B.R., and Jacobs, W.R. Jr. (1994). Isolation and characterization of the aspartokinase and aspartate semialdehyde dehydrogenase operon from mycobacteria. *Mol Microbiol* 11, 629–639.
- Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S.V., Eiglmeier, K., Gas, S., Barry, C.E., *et al.* (1998). Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 393, 537–544. *Nature* 396, 190–198 (Erratum).
- Corbett, E.L., Watt, C.J., Walker, N., Maher, D., Williams, B.G., Raviglione, M.C., and Dye, C. (2003). The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Arch Intern Med* 163, 1009–1021.
- DeLano, W.L., and Lam, J.W. (2005). PyMOL: A communications tool for computational models. *Abstracts of Papers of the American Chemical Society* 230, U1371–U1372.
- Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 60, 2126–2132.
- Faehnle, C.R., Liu, X., Pavlovsky, A., and Viola, R.E. (2006). The initial step in the archaeal aspartate biosynthetic pathway catalyzed by a monofunctional aspartokinase. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 62, 962–966.
- Fleischmann, R.D., Alland, D., Eisen, J.A., Carpenter, L., White, O., Peterson, J., DeBoy, R., Dodson, R., Gwinn, M., Haft, D., *et al.* (2002). Whole-genome comparison of *Mycobacterium tuberculosis* clinical and laboratory strains. *J Bacteriol* 184, 5479–5490.
- Gilker J.M., and Jucker M.T. (1997). *Mycobacterium tuberculosis* ask-alpha, ask-beta and asd genes. Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.
- Grant, G.A. (2006). The ACT domain: a small molecule binding domain and its role as a common regulatory element. *J Biol Chem* 281, 33825–33829.
- Hayward, S., and Lee, R.A. (2002). Improvements in the analysis of domain motions in proteins from conformational change: DynDom version 1.50. *J Mol Graph Model* 21, 181–183.
- Kotaka, M., Ren, J., Lockyer, M., Hawkins, A.R., and Stammers, D.K. (2006). Structures of R- and T-state *Escherichia coli* aspartokinase III. Mechanisms of the allosteric transition and inhibition by lysine. *J Biol Chem* 281, 31544–31552.
- Mas-Droux, C., Curien, G., Robert-Genthon, M., Laurencin, M., Ferrer, J.L., and Dumas, R. (2006). A novel organization of ACT domains in allosteric enzymes revealed by the crystal structure of *Arabidopsis* aspartate kinase. *Plant Cell* 18, 1681–1692.
- Matthews, B.W. (1968). Solvent content of protein crystals. *J Mol Biol* 33, 491–497.
- McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. *J Appl Crystallogr* 40, 658–674.
- Nishiyama, M., Kukimoto, M., Beppu, T., and Horinouchi, S. (1995). An operon encoding aspartokinase and purine phosphoribosyl-transferase in *Thermus flavus*. *Microbiology* 141, 1211–1219.
- Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction data collected in oscillation mode. *Macromolecular Crystallography . Pt A* 276, 307–326.
- Rapaport, E., Levina, A., Metelev, V., and Zamecnik, P.C. (1996). Antimycobacterial activities of antisense oligodeoxynucleotide phosphorothioates in drug-resistant strains. *Proc Natl Acad Sci U S A* 93, 709–713.
- Robin, A.Y., Cobessi, D., Curien, G., Robert-Genthon, M., Ferrer, J.L., and Dumas, R. (2010). A new mode of dimerization of allosteric enzymes with ACT domains revealed by the crystal structure of the aspartate kinase from *Cyanobacteria*. *J Mol Biol* 399, 283–293.
- Rognes, S.E., Lea, P.J., and Mifflin, B.J. (1980). S-adenosylmethionine—a novel regulator of aspartate kinase. *Nature* 287, 357–359.
- Schuldt, L., Suchowersky, R., Veith, K., Mueller-Dieckmann, J., and Weiss, M.S. (2011). Cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of the regulatory domain of aspartokinase (Rv3709c) from *Mycobacterium tuberculosis*. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 67, 380–385.
- Tomioaka, H., and Namba, K. (2006). [Development of antituberculous drugs: current status and future prospects]. *Kekkaku* 81, 753–774.
- Yoshida, A., Tomita, T., Kono, H., Fushinobu, S., Kuzuyama, T., and Nishiyama, M. (2009). Crystal structures of the regulatory subunit of Thr-sensitive aspartate kinase from *Thermus thermophilus*. *FEBS J* 276, 3124–3136.
- Yoshida, A., Tomita, T., Kurihara, T., Fushinobu, S., Kuzuyama, T., and Nishiyama, M. (2007a). Structural Insight into concerted inhibition of alpha 2 beta 2-type aspartate kinase from *Corynebacterium glutamicum*. *J Mol Biol* 368, 521–536.
- Yoshida, A., Tomita, T., Kuzuyama, T., and Nishiyama, M. (2007b). Purification, crystallization and preliminary X-ray analysis of the regulatory subunit of aspartate kinase from *Thermus thermophilus*. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 63, 96–98.
- Yoshida, A., Tomita, T., Kuzuyama, T., and Nishiyama, M. (2010). Mechanism of concerted inhibition of alpha2beta2-type hetero-oligomeric aspartate kinase from *Corynebacterium glutamicum*. *J Biol Chem* 285, 27477–27486.